Get the Stockscreener App
29.71
4.81%
-1.50
Veracyte Inc stock is traded at $29.71, with a volume of 1.37M.
It is down -4.81% in the last 24 hours and down -8.92% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
See More
Previous Close:
$31.21
Open:
$31.5
24h Volume:
1.37M
Relative Volume:
1.36
Market Cap:
$2.38B
Revenue:
$399.58M
Net Income/Loss:
$-54.04M
P/E Ratio:
-39.61
EPS:
-0.75
Net Cash Flow:
$40.13M
1W Performance:
-2.11%
1M Performance:
-8.92%
6M Performance:
-18.56%
1Y Performance:
+44.01%
1-Day Range:
$28.81
$32.35
1-Week Range:
$27.24
$32.35
52-Week Range:
$19.73
$47.32
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
29.71 | 2.38B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up - Zacks Investment Research
Veracyte First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight - GuruFocus
Veracyte Inc earnings beat by $0.29, revenue topped estimates - Investing.com Nigeria
Veracyte (VCYT) Target Price Lowered by UBS | VCYT Stock News - GuruFocus
What Makes Veracyte (VCYT) a New Buy Stock - Yahoo Finance
Veracyte shares target cut to $41 by Needham, keeps buy rating - Investing.com Nigeria
Veracyte, Inc. (NASDAQ:VCYT) Q1 2025 Earnings Call Transcript - Insider Monkey
UBS Adjusts Price Target for Veracyte (VCYT) Amid Growth Potential | VCYT Stock News - GuruFocus
UBS Cuts Price Target on Veracyte to $42 From $49, Keeps Buy Rating - marketscreener.com
VERACYTE, INC. SEC 10-Q Report - TradingView
Breaking Down Veracyte: 7 Analysts Share Their Views - Benzinga
Veracyte (VCYT) Target Price Lowered by Needham Analyst | VCYT Stock News - GuruFocus
Veracyte: Q1 Earnings Snapshot - Norwalk Hour
Veracyte Inc (VCYT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions - Yahoo Finance
Veracyte Reports Strong Q1 2025 Financial Growth - TipRanks
Veracyte (VCYT) Reports Strong Q1 Growth Driven by Decipher and Afirma - GuruFocus
Veracyte Announces First Quarter 2025 Financial Results - BioSpace
Veracyte Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Veracyte Q1 2025 sees strong revenue growth, stock surges - Investing.com Australia
Veracyte Inc (VCYT) Q1 2025 Earnings: EPS of $0.09 Beats Estimat - GuruFocus
Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Veracyte Q1 2025 slides: 18% revenue growth, transition to profitability By Investing.com - Investing.com South Africa
Veracyte Q1 2025 slides: 18% revenue growth, transition to profitability - Investing.com Australia
Veracyte (VCYT) Reaffirms 2025 Revenue Outlook Amid Strong Performance | VCYT Stock News - GuruFocus
Veracyte (VCYT) Exceeds Q1 Revenue Projections with Strong Testing Volume Growth | VCYT Stock News - GuruFocus
Veracyte Inc (VCYT) Q1 2025 Earnings: EPS of $0.09 Beats Estimates, Revenue Surges to $114.5 Million - GuruFocus
Earnings Flash (VCYT) VERACYTE INC. Reports Q1 Revenue $114.5M, vs. FactSet Est of $111.3M - marketscreener.com
Breaking Down the Benefits of Clinical Trial Participation in Cancer Care - Curetoday
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer - BioSpace
Veracyte launches prostate metastatic test - MSN
Crafting an Individual Treatment Plan for Patients With Prostate Cancer - Curetoday
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms - Benzinga
Veracyte launches metastatic prostate cancer test - Investing.com
Veracyte launches metastatic prostate cancer test By Investing.com - Investing.com South Africa
Veracyte launches prostate metastatic test (VCYT:NASDAQ) - Seeking Alpha
Veracyte (VCYT) Boosts Cancer Care with New Genomic Classifier Launch | VCYT Stock News - GuruFocus
Veracyte Announces Expanded Availability of Decipher Prostate Te - GuruFocus
Veracyte (VCYT) Boosts Cancer Care with New Genomic Classifier L - GuruFocus
Veracyte Announces Expanded Availability Of Decipher Prostate Test To Patients With Metastatic Prostate Cancer - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Veracyte Announces Multiple Abstracts Demonstrating Power of Dec - GuruFocus
Breakthrough Cancer Insights: 18 New Studies Confirm Veracyte Decipher Test's Power in Prostate and Bladder Cancer - Stock Titan
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release - 01net
Veracyte data joins NCI SEER database for research By Investing.com - Investing.com South Africa
Veracyte Announces Decipher Prostate Genomic Classifier Results - GuruFocus
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):